RT Journal Article
SR Electronic
T1 Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors
JF Evidence Based Medicine
JO Evid Based Med
FD BMJ Publishing Group Ltd
SP 7
OP 8
DO 10.1136/ebm1100
VO 16
IS 1
A1 Giuseppe Derosa
YR 2011
UL http://ebm.bmj.com/content/16/1/7.abstract
AB